¿¬¼ö°­ÁÂ
(¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦36Â÷ Ãá°èÇмú´ëȸ : 2021-04-17
(¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦36Â÷ Ãá°èÇмú´ëȸ : 2021-04-17
±³À°ÀÏÀÚ : 2021-04-17
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦36Â÷ Ãá°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÇѼ¼¹Ì
¿¬¶ôó : 02-512-0044  
À̸ÞÀÏ : office@sgo.or.kr      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í Àü¹®ÀÇ 60,000Àü°øÀÇ 45,000ÀϹÝÀÇ,¿¬±¸¿ø,°£È£»ç 30,000 65¼¼ÀÌ»ó ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04-17 Channel 1 & 2 09:00~09:10 Opening Remarks  ±è¿µÅÂ(´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå) 
±³À°½Ã°£ 04-17 Channel 1 & 2 09:10~09:30 Impact of COVID-19 on the care of gynecologic cancer patients requiring surgery  Sudha Sundar(Univ. of Birmingham UK) 
±³À°½Ã°£ 04-17 Channel 1 & 2 09:30~09:35 Designated discussion  ±Çº´¼ö(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 & 2 09:35~09:45 COVID-19 ´ëÀ¯Çà°ú ¾ÏȯÀÚ Ä¡·á, ÀÓ»ó½ÃÇè ¹× ¹é½Å Á¢Á¾  ¹Ú¼öÁø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 & 2 09:45~09:50 Designated discussion  ¹Î°æÁø(°í·ÁÀÇ´ë) 
Åä·Ð 04-17 Channel 1 & 2 09:50~10:00 Discussion  () 
±³À°½Ã°£ 04-17 Channel 1 & 2 10:00~10:15 Surgical quality of ovarian cancer: how to evaluate and improve?  Àå¼®ÁØ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 & 2 10:15~10:30 Designated discussion  À̼ºÁ¾À̽ÅÈ­ÀÌÀºÁÖ(°¡Å縯ÀÇ´ë¿ï»êÀÇ´ëÁß¾ÓÀÇ´ë) 
È޽Ġ04-17 Channel 1 & 2 10:30~10:50 Break Time  () 
±³À°½Ã°£ 04-17 Channel 1 & 2 10:50~11:00 Drug repositioning for ovarian cancer targeting mevalonate pathway  Yusuke Kobayashi(Keio Univ. Japan) 
±³À°½Ã°£ 04-17 Channel 1 & 2 11:00~11:10 Novel nanomedicine for epithelial ovarian cancer : cathepsin B-cleavable peptide-conjugated doxorubicin prodrug  Á¤¼ö¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 & 2 11:10~11:20 Multi-Omics and Therapeutically Applicable Research of Ovarian Cancer  Gang Chen(Tongji Medical College China) 
±³À°½Ã°£ 04-17 Channel 1 & 2 11:20~11:30 Designated discussion  ³²ÀºÁö(¿¬¼¼ÀÇ´ë) 
Åä·Ð 04-17 Channel 1 & 2 11:30~11:35 Discussion  () 
±³À°½Ã°£ 04-17 Channel 1 & 2 11:35~11:45 Risk of adverse obstetric outcomes in patients with a history of endometrial cancer: a population-based cohort study  ½É½ÂÇõ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 & 2 11:45~11:55 Comparisons of survival between bevacizumab vs. olaparib in platinum-sensitive, relapsed ovarian cancer (KGOG 3052)  ±è¼¼ÀÍ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 & 2 11:55~12:05 A computational model for identification of parametrial invasion in women with early-stage cervical cancer  Kittipat Charoenkwan(Chiang Mai Univ. Thailand) 
±³À°½Ã°£ 04-17 Channel 1 & 2 12:05~12:15 Designated discussion  ¼Û¿ëÁß(ºÎ»êÀÇ´ë) 
Åä·Ð 04-17 Channel 1 & 2 12:15~12:20 Discussion  () 
±³À°½Ã°£ 04-17 Channel 1 12:20~12:40 PARP inhibitors for advanced or recurrent ovarian cancer  B. Monk(Univ. of Arizona USA) 
±³À°½Ã°£ 04-17 Channel 1 12:40~13:00 PBM in patients with gynecologic cancer  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 04-17 Channel 2 12:20~12:40 Lenvatinib plus pembrolizumab for recurrent endometrial cancer  ±è±âµ¿(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 2 12:40~13:00 Time to Navigate Patient Journey with Optimal Front-line Treatment in Advanced Ovarian Cancer  ÀÌÁ¤¿ø(¼º±Õ°üÀÇ´ë) 
½Ä»ç 04-17 Channel 1 & 2 13:00~14:00 Lunch  () 
±³À°½Ã°£ 04-17 Channel 1 14:00~14:07 Immunohistochemical and genetic characteristics of invasive stratified mucin-producing carcinoma of the uterine cervix  ¹ÚÀºÇâ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 14:07~14:14 Circulating tumor cells as a predictive marker for treatment monitoring of ovarian cancer patients.  À̽¹Ì(°è¸íÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 14:14~14:21 C-peptide prevents hyperglycemia-induced TGase2 activation in ovarian cancer cells  ¿À¿µÅÃ(°­¿øÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 14:21~14:30 Distillation  È«ÁøÈ­(°í·ÁÀÇ´ë) 
Åä·Ð 04-17 Channel 1 14:30~14:40 Discussion  () 
±³À°½Ã°£ 04-17 Channel 1 14:40~14:47 Accuracy of HPV tests on urine versus clinician-collected samples for the detection of cervical precancer: meta-analysis  Á¶Çö¿õ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 14:47~14:54 Dynamics of Fecal Microbiota with and without Invasive Cervical Cancer and Its Application in Early Diagnosis  ÀÌÀ±Èñ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 14:54~15:01 Concerns for a long lead time on confirmatory test after abnormal Pap test in the COVID-19 era  ±è¹Ì¼±(Â÷ÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 15:01~15:10 Distillation  ±è¹Ì°æ(ÀÌÈ­ÀÇ´ë) 
Åä·Ð 04-17 Channel 1 15:10~15:20 Discussion  () 
±³À°½Ã°£ 04-17 Channel 1 15:20~15:27 Determining the extent of lymphadenectomy in patients with endometrial cancer  ½Å¿ø±³(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 04-17 Channel 1 15:27~15:34 Nomogram for microscopic lymph node metastasis in surgically staged endometrioid endometrial cancer patients  °øÅ¿í(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 15:34~15:41 Incidence and risk factors of VTE in patients with cervical cancer using the Korean national health insurance data  À̹æÇö(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 15:41~15:48 Survival analysis of chemoradiotherapy versus chemotherapy alone for stage III endometrial cancer: a multicenter study  À¯Áö±Ù(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 15:48~16:00 Distillation  ÃÖ¹Îö(Â÷ÀÇ´ë) 
Åä·Ð 04-17 Channel 1 16:00~16:10 Discussion  () 
È޽Ġ04-17 Channel 1 16:10~16:20 Break Time  () 
±³À°½Ã°£ 04-17 Channel 2 14:00~14:10 WHO classification of female genital tumors, the 5th ed.  ÀÌö(¼­¿ïÀÇ´ë º´¸®°ú) 
±³À°½Ã°£ 04-17 Channel 2 14:10~14:20 ESMO-ESGO new guideline for endometrial cancer: focusing on molecular classifier  Á¶ÇѺ°(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 2 14:20~14:40 Panel discussion  ±è¹Î±ÔÀ̸¶¸®¾ÆÀÌÁ¤À½(¼º±Õ°üÀÇ´ë ¼­¿ïÀÇ´ë °¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 2 14:40~14:50 Adjuvant therapy for postoperative cervical cancer  ±è¿ë¹è(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇÐÈ­) 
±³À°½Ã°£ 04-17 Channel 2 14:50~15:00 Intraoperative detection of lymph node metastasis:  ÁÖ¿ø´ö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 2 15:00~15:20 Panel discussion  ½Å¼ÒÁøÀÓ°¡¿ø¹®ÀçÈñ(°è¸íÀǴ뵿±¹ÀÇ´ë¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 2 15:20~15:30 Immune checkpoint inhibitors in recurrent  ½É½ÂÇõ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 2 15:30~15:40 Candidate biomarkers for immune checkpoint inhibitors  È«¼÷Èñ(°¡Å縯ÀÇ´ë Á¾¾ç³»°ú) 
±³À°½Ã°£ 04-17 Channel 2 15:40~16:00 Panel discussion  ³ëÁÖ¿ø¹®¿ëÈ­À¯ÇåÁ¾(Â÷ÀÇ´ë Â÷ÀÇ´ë Ç÷¾×Á¾¾ç³»°ú Ãæ³²ÀÇ´ë) 
È޽Ġ04-17 Channel 2 16:00~16:20 Break Time  () 
±³À°½Ã°£ 04-17 Channel 1 & 2 16:20~16:35 Case presentation & voting management  ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-17 Channel 1 & 2 16:35~16:50 Panel discussion  ¹ÚÁ¤¿­¹èÀ縸ȫ´ë±â(¿ï»êÀÇ´ëÇѾçÀÇ´ë°æºÏÀÇ´ë) 
±âŸ 04-17 Channel 1 & 2 16:50~17:00 ½Ådzȣ¿ùÇмú»ó ¹× JGO Best Reviewer Award ¼ö»óÀÚ ¹ßÇ¥  () 
±âŸ 04-17 Channel 1 & 2 17:00~17:10 Closing Remarks  () 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ÀÏ¿ø¿ª»ç Bµ¿ 9Ãþ È÷Æ÷Å©¶óÅ×½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,206 , ´ñ±Û¼ö : 0

[ºÎ»ê] ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷) : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑ°ñÀýÇÐȸ ´ã´çÀÚ : Á¤À¯Áø ¿¬¶ôó : 031-551

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,011 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,210 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ BPEX 5Ãþ ÄÁÆÛ·±½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,214 , ´ñ±Û¼ö : 0

[´ë±¸] Á¦27Â÷ ´ëÇѽÉÀåÇÐȸ ´ë±¸°æºÏÁöȸ ÀÓ»ó½ÉÀåÇÐ ¿¬¼ö°­Á : 2024-03-24

±³À°ÀÏÀÚ : 2024-03-24 ±³À°Àå¼Ò : ´ë±¸ ÀÎÅÍºÒ°í ¸¸Ã̵¿ ÄÁº¥¼ÇȦ 2Ãþ ±³À°ÁÖÁ¦ : Á¦27Â÷ ´ëÇѽÉÀåÇÐȸ ´ë±¸°æºÏÁöȸ ÀÓ»ó½ÉÀåÇÐ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ ½ÃÇà±â

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,251 , ´ñ±Û¼ö : 0